Atossa Genetics (ATOS) to Release Quarterly Earnings on Wednesday

Atossa Genetics (NASDAQ:ATOS) is projected to announce its Q4 2025 results before the market opens on Wednesday, April 1st. Analysts expect the company to announce earnings of ($1.05) per share for the quarter. Parties are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Friday, April 3, 2026 at 9:30 AM ET.

Atossa Genetics Stock Performance

Atossa Genetics stock opened at $5.51 on Wednesday. Atossa Genetics has a 1 year low of $3.76 and a 1 year high of $19.35. The firm has a 50 day moving average price of $5.95 and a 200 day moving average price of $10.05. The company has a market cap of $47.44 million, a price-to-earnings ratio of -1.53 and a beta of 1.42.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in ATOS. Ameriprise Financial Inc. acquired a new stake in Atossa Genetics during the 2nd quarter valued at $2,468,000. Renaissance Technologies LLC grew its stake in shares of Atossa Genetics by 33.2% during the fourth quarter. Renaissance Technologies LLC now owns 2,062,838 shares of the company’s stock valued at $1,217,000 after acquiring an additional 514,175 shares in the last quarter. Jane Street Group LLC acquired a new stake in shares of Atossa Genetics during the second quarter valued at about $381,000. Qube Research & Technologies Ltd increased its position in shares of Atossa Genetics by 357.4% during the second quarter. Qube Research & Technologies Ltd now owns 416,374 shares of the company’s stock worth $346,000 after acquiring an additional 325,340 shares during the last quarter. Finally, Vanguard Group Inc. lifted its stake in shares of Atossa Genetics by 4.2% in the third quarter. Vanguard Group Inc. now owns 6,078,844 shares of the company’s stock worth $5,270,000 after acquiring an additional 245,717 shares in the last quarter. 12.74% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

ATOS has been the topic of several research reports. Ascendiant Capital Markets increased their target price on Atossa Genetics from $116.25 to $120.00 and gave the stock a “buy” rating in a research report on Monday, December 8th. Weiss Ratings restated a “sell (d-)” rating on shares of Atossa Genetics in a report on Wednesday, January 21st. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, Atossa Genetics has a consensus rating of “Hold” and an average target price of $95.00.

About Atossa Genetics

Atossa Genetics, Inc is a clinical-stage biotechnology company based in Seattle, Washington, focused on developing therapeutics and diagnostic products for breast cancer and other breast-related conditions. The company’s mission centers on delivering targeted, minimally invasive solutions that address early detection, treatment, and prevention in women at risk for or diagnosed with breast malignancies.

The company’s pipeline includes Z-Endoxifen, an oral formulation of endoxifen designed to treat and prevent estrogen receptor–positive breast cancers, particularly in patients with ductal carcinoma in situ or those at high risk of recurrence.